LON:TILS Tiziana Life Sciences (TILS) Share Price, News & Analysis GBX 58.50 +4.50 (+8.33%) (As of 10/20/2021) Add Compare Share Share Today's Range 45▼ 5950-Day Range 58.50▼ 58.5052-Week Range 30▼ 195Volume297,127 shsAverage Volume522,223 shsMarket Capitalization£113.85 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Tiziana Life Sciences alerts: Email Address Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Tiziana Life Sciences Stock (LON:TILS)Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. Its product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such as GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma. The company also develops anti-IL6R (TZLS-501), a human anti-interleukin-6 receptor monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat COVID-19 patients with severe respiratory symptoms. It has a collaboration agreement with FHI Clinical Inc. to conduct a phase 2 clinical trial for treating hospitalized severe COVID-19 patients with intranasal foralumab, a human anti-CD3 monoclonal antibody. The company was incorporated in 1998 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited.Read More TILS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TILS Stock News HeadlinesJuly 24 at 12:17 PM | msn.comTiziana spikes on FDA fast track tag for lead assetDecember 6, 2023 | proactiveinvestors.comTiziana Life Sciences to present immunotherapy updates at...Tiziana Life Sciences to present immunotherapy updates at Webull...July 26, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.October 18, 2023 | markets.businessinsider.comTiziana : FDA Allows Multiple Sclerosis Patients To Take Home & Self-administer Intranasal ForalumabOctober 18, 2023 | proactiveinvestors.comTiziana Life Sciences: FDA signs off on home-based protocol fo MS treatmentOctober 16, 2023 | markets.businessinsider.comTiziana Life Sciences Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal ForalumabOctober 13, 2023 | proactiveinvestors.comTiziana Life Sciences reports six-month PET scan results for MS patientsSeptember 26, 2023 | uk.investing.comTiziana Life Sciences Ltd (0RP)July 26, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.September 26, 2023 | tmcnet.comTiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple SclerosisAugust 23, 2023 | technews.tmcnet.comTiziana Life Sciences Announces Foralumab Presentation by Dr. Howard Weiner at the Annual Meeting of the International Society of NeuroimmunologyAugust 15, 2023 | msn.comTiziana Life Sciences’ stock soars 54% premarket after FDA clear path for trial of intranasal treatment for Alzheimer’s diseaseApril 21, 2023 | benzinga.comTiziana Life Sciences To Submit Alzheimer's IND In Q2 2023, Seeks $3 Million From An Alzheimer's Foundation To Support Phase 2a TrialMarch 19, 2023 | seekingalpha.comTiziana Life Sciences CEO purchases sharesSeptember 25, 2022 | finanznachrichten.deTiziana Life Sciences Ltd.: Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical OfficerSeptember 9, 2022 | benzinga.comTiziana Life Sciences Announces Purchase of Common Shares by Chief Medical OfficerSeptember 6, 2022 | yahoo.comHarry Styles and Olivia Wilde Hit Their First Red Carpet Together Amid 'Don't Worry Darling' DramaJuly 2, 2022 | proactiveinvestors.comTiziana Life Sciences' half-term report reveals it has made progress on all frontsSee More Headlines Receive TILS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tiziana Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/30/2020Today7/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:TILS Previous SymbolLON:ADI CUSIPN/A CIKN/A Webwww.tizianalifesciences.com Phone+44-20-74952379FaxN/AEmployees11Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio2.36 Current Ratio6.54 Quick Ratio6.41 Sales & Book Value Annual Sales£-3,595,000.00 Price / Sales-31.67 Cash FlowGBX 25.70 per share Price / Cash Flow2.28 Book ValueGBX 23.50 per share Price / Book2.49Miscellaneous Outstanding Shares194,612,000Free FloatN/AMarket Cap£113.85 million OptionableNot Optionable BetaN/A Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Gabriele Marco Antonio Cerrone M.B.A. (Age 49)MBA, Founder & Exec. Chairman Comp: $13.76MDr. Kunwar Shailubhai (Age 63)CEO, Chief Scientific Officer & Exec. Director Comp: $810kDr. Andrea BrancaleScientific FounderMr. Richard Clarkson Ph.D.Scientific FounderMr. Andrew Westwell Ph.D.Scientific FounderMs. Keeren Shah (Age 44)Fin. Director Dr. Thomas H. Adams (Age 78)Head of Drug Devel. & Exec. Director Dr. Neil Graham M.P.H. (Age 62)MBBS, M.D., MPH, Chief Medical Officer Dr. Napoleone Ferrara (Age 63)Chairman of Scientific Advisory Board Prof. Roberto PellicciariConsultantMore ExecutivesKey CompetitorsOxford BiomedicaLON:OXBHorizon Discovery Group plc (HZD.L)LON:HZDAvacta GroupLON:AVCTVerona Pharma plc (VRP.L)LON:VRPBioventixLON:BVXPView All Competitors TILS Stock Analysis - Frequently Asked Questions How have TILS shares performed this year? Tiziana Life Sciences' stock was trading at GBX 58.50 at the beginning of the year. Since then, TILS stock has increased by 0.0% and is now trading at GBX 58.50. View the best growth stocks for 2024 here. How were Tiziana Life Sciences' earnings last quarter? Tiziana Life Sciences PLC (LON:TILS) announced its quarterly earnings results on Wednesday, September, 30th. The biotechnology company reported ($2.60) earnings per share for the quarter, beating analysts' consensus estimates of ($4.00) by $1.40. How do I buy shares of Tiziana Life Sciences? Shares of TILS stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of Tiziana Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tiziana Life Sciences investors own include Synergy Pharmaceuticals (SGYP), Micron Technology (MU), ServiceNow (NOW), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD) and Broadcom (AVGO). This page (LON:TILS) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tiziana Life Sciences PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Tiziana Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.